TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05706090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl will be added
Description: If adequate anagesia is not provided with the block, 1 microgram/kg of fentanyl will be added

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl will be added
Description: If adequate anagesia is not provided with the block, 1 microgram/kg of fentanyl will be added

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: If adequate anagesia is not provided with the block, general anesthesia will be administered.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: If adequate anagesia is not provided with the block, general anesthesia will be administered.
Study: NCT01758484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: palliative care
Description: Undergo supportive care intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT01279343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley bulb
Description: This is a randomized trial comparing foley bulb with the use of misoprostol versus use of misoprostol alone for cervical ripening and labor induction.
Study: NCT03287414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAY736
Description: 300 mg VAY736 administered subcutaneously every 4 weeks for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously every 4 weeks for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care (SoC)
Description: Background standard-of-care treatment for IPF: nintedanib, pirfenidone, or no background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC)
Description: Background standard-of-care treatment for IPF: nintedanib, pirfenidone, or no background therapy
Study: NCT02110745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevofluorane
Description: Comparison of different induction drugs and techniques

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Comparison of different induction drugs and techniques
Study: NCT01981954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: Oral suspension
Study: NCT01865916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol (PEG) and 15 mg Bisacodyl
Description: Subjects will be asked to take split dose of 2L PEG and 3 tablets of 5 mg Bisacodyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol (PEG) + ascorbic acid
Description: Subjects will be asked to take split dose of 2L PEG and vitamin C
Study: NCT01960530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone granules
Description: Multi-particulate granules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone Tablet
Description: Standard hydrocortisone tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: i.v. Hydrocortisone Injection
Description: Standard hydrocortisone solution for intravenous injection

Intervention type: OTHER
Group type: OTHER
Intervention: Dexamethasone
Description: Challenge agent
Study: NCT01301274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hypotonic
Description: 0.45% NaCl/5% dextrose IV maintenance fluids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotonic
Description: 0.9% NaCl/5% dextrose IV maintenance fluids
Study: NCT05601934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurophysiological Facilitation Techniques
Description: Increased enlargement of the ribs during inspiration and increased movement in the epigastric region and tone of the abdominal muscles also decreased respiratory rate are some of the changes that occur after these stimuli. In addition to these, involuntary increase in cough, sputum production also decrease in pathological sounds felt on auscultation, decrease in aspiration requirement, rapid return in chest wall stabilization and improvement in respiratory pattern can be observed after application with this application, positive and long-term effective results can be seen in a short time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurophysiological Facilitation Techniques
Description: Increased enlargement of the ribs during inspiration and increased movement in the epigastric region and tone of the abdominal muscles also decreased respiratory rate are some of the changes that occur after these stimuli. In addition to these, involuntary increase in cough, sputum production also decrease in pathological sounds felt on auscultation, decrease in aspiration requirement, rapid return in chest wall stabilization and improvement in respiratory pattern can be observed after application with this application, positive and long-term effective results can be seen in a short time.
Study: NCT03322098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Atropine injection (0.01 mg/kg, max 0.5 mg) within 3 minutes before spinal anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) within 3 minutes before spinal anesthesia
Study: NCT01468441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Triptorelin (0.1 mg, Gonapeptyl® Daily; Ferring, Kiel, Germany) in alternate-days from Day 1 of the menstrual cycle until the day of hCG administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix
Description: When patients presented at least two follicles ≥ 14mm upon scan on days 7- 9, GnRH antagonist (cetrorelix, 0.25 mg/day, Cetrotide®; EMD Serono, Inc, Rockland, MA, USA) administration is started and continued until hCG administration.
Study: NCT03269240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acquisition of Knowledge and clinical skills
Description: LDHF is a novel training approach that is being compared to the traditional training approach

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acquisition of Knowledge and clinical skills
Description: LDHF is a novel training approach that is being compared to the traditional training approach

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Onsite training
Description: Participants are training at their health facilities

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Off-site training
Description: Participants from different health facilities are gathered together in a central location for training, away from their workplaces
Study: NCT03684122

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of Umbilical cord derived MSCs
Description: Allogenic umbilical cord derived MSCs which are to be injected intrathecally and intravenously as a treatment option for consenting PD patients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of Umbilical cord derived MSCs
Description: Allogenic umbilical cord derived MSCs which are to be injected intrathecally and intravenously as a treatment option for consenting PD patients
Study: NCT03612492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: Esmolol group (EG) will receive a bolus of esmolol 1.5mg / kg in 10 min following by continuous infusion at a rate of 0.1mg / kg / min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: Esmolol group (EG) will receive a bolus of esmolol 1.5mg / kg in 10 min following by continuous infusion at a rate of 0.1mg / kg / min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine (LG) group will received lidocaine bolus of 1.5mg / kg in 10 min following by continuous infusion at a rate of 1.5mg / kg / h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine (LG) group will received lidocaine bolus of 1.5mg / kg in 10 min following by continuous infusion at a rate of 1.5mg / kg / h.
Study: NCT03207139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 PSMA ligand
Description: For PET/CT PSMA ligand scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA ligand . Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA ligand and received PET/CT scan 60 minutes later. The data acquisition begin with non-contrast CT at 120kVp, automated mAs, and a pitch of 1.5, followed by PET acquisition from the mid-thigh to skull-base, 3 minutes each bed. After image acquisition, the subject will be observed for half an hour, and will be discharged if no adverse event happens.~The estimated organ doses show that the kidneys and the urinary bladder wall were the organs with the highest dose. As presented, the effective doses for patients were 0.023 mSv/MBq ± 15% (maximum deviation), leading to an effective dose of 3.4 mSv for an injected activity of 150 MBq.
Study: NCT03945864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: antimicrobial synthetic bone graft
Description: It will be determined whether the silver ion-doped antimicrobial synthetic bone graft that has the capacity to fill the bone voids also has the capacity to treat the infection in the bone in 12 patients with chronic osteomyelitis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: parentaral antimicrobials and pure bone grafts
Description: Historical data of the department will be used for comparison of the results
Study: NCT01920399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAZ-AVI
Description: A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline
Description: A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
Study: NCT01309399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: six weeks of teriparatide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01680393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sequential compression device
Description: a sequential compression device will be applied to the legs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TED stockings
Description: TED stockings will be applied to the patients legs during surgery
Study: NCT03076944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UltraEZ
Description: Prophylaxis, apply uniformly on the teeth, wait 15 minutes, remove the gel from the teeth with cotton and abundant water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UltraEZ
Description: Prophylaxis, apply uniformly on the teeth, wait 15 minutes, remove the gel from the teeth with cotton and abundant water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enamelast
Description: Prophylaxis; dry the teeth; apply uniformly on the teeth with a thin layer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enamelast
Description: Prophylaxis; dry the teeth; apply uniformly on the teeth with a thin layer.
Study: NCT04209855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: Mirvetuximab Soravtansine will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan will be administered per dose and schedule specified in the arm.
Study: NCT02944526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Monohydrochloride
Description: Suprascapular nerve block under ultrasound control: injection of 5ml Ropivacaine HCL 2mg /ml
Study: NCT04209855

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin
Description: Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.
Study: NCT02210793

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transepithelial PRK

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK
Study: NCT02329184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYK-461
Study: NCT02730182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: altitude exposure
Description: altitude exposure
Study: NCT01057784

Intervention type: PROCEDURE
Intervention: Bariatric surgery.
Description: Bariatric Surgery

Intervention type: PROCEDURE
Intervention: Bariatric surgery.
Description: Bariatric Surgery
Study: NCT03062202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SilverCloud
Description: SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions for all of the anxiety disorders (panic disorder, social anxiety, phobias, GAD, health anxiety, OCD), depression and also comorbid depression and anxiety. The programs for the treatment of depression and anxiety employ several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social. Research on the SilverCloud interventions has yielded significant clinical outcomes (Richards et al., 2015).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SilverCloud
Description: SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions for all of the anxiety disorders (panic disorder, social anxiety, phobias, GAD, health anxiety, OCD), depression and also comorbid depression and anxiety. The programs for the treatment of depression and anxiety employ several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social. Research on the SilverCloud interventions has yielded significant clinical outcomes (Richards et al., 2015).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SilverCloud
Description: SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions for all of the anxiety disorders (panic disorder, social anxiety, phobias, GAD, health anxiety, OCD), depression and also comorbid depression and anxiety. The programs for the treatment of depression and anxiety employ several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social. Research on the SilverCloud interventions has yielded significant clinical outcomes (Richards et al., 2015).
Study: NCT02516722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Intra-Vascular UltraSound (TIVUS™) System
Description: The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation.~Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation.
Study: NCT02975635

Intervention type: OTHER
Intervention: Questionnaire
Description: Patients are given a questionnaire with items related to personality and behaviour.

Intervention type: OTHER
Intervention: Questionnaire
Description: Patients are given a questionnaire with items related to personality and behaviour.
Study: NCT02944526

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Concentrate
Description: Placebo suprascapular nerve block under ultrasound control: injection of 5ml physiological / isotonic saline
Study: NCT04433962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Study: NCT00830622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cell Phone Intervention
Description: Participant receives weekly SMS text messages from the health care provider.
Study: NCT01580839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue Plasminogen Activator (Alteplase)
Description: 0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
Study: NCT05613114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalfampridine 10 MG
Description: The participants in the experimental group received dalfampridine administered as 10 mg extended-release tablets every twelve hours for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group received a placebo drug with the same administration method (2 times per week for the total duration of 8 weeks).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Conventional physiotherapy program including stretching and flexibility, strengthening, walking and balance exercises which were mainly focused on the lower limbs and improving walking. The program was applied 2 times per week for the total duration of 8 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physiotherapy
Description: Conventional physiotherapy program including stretching and flexibility, strengthening, walking and balance exercises which were mainly focused on the lower limbs and improving walking. The program was applied 2 times per week for the total duration of 8 weeks.
Study: NCT04665024

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoperative chest physiotherapy
Description: The patients were approached to partake in the investigation after they got full clarifications about the point of study. They were allocated into two groups and reassurance was achieved about the absence of any side effects.Furthermore, the examination was approved by the ethical committee.~Effects of preoperative chest physiotherapy were compared between two groups, by measuring the lung functions, oxygen saturation, pulmonary complications and length of hospital staying. Lung functions were completed by utilizing spirometry parameters, oxygen saturation was measured by pulse oximeter and pulmonary complications were diagnosed by specialist doctors.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: postoperative chest physiotherapy
Description: Postoperative chest physiotherapy made in both two groups was similar to the preoperative chest physiotherapy but this was achieved by physiotherapists and made once a day for 10-25 minutes depending on the lectures of postoperative days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: postoperative chest physiotherapy
Description: Postoperative chest physiotherapy made in both two groups was similar to the preoperative chest physiotherapy but this was achieved by physiotherapists and made once a day for 10-25 minutes depending on the lectures of postoperative days.
Study: NCT00855010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: pioglitazone 45 mg daily
Study: NCT04713878

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal stem cells
Description: Intravenous infusion of Mesenchymal stem cells

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal stem cells
Description: Intravenous infusion of Mesenchymal stem cells

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal stem cells
Description: Intravenous infusion of Mesenchymal stem cells
Study: NCT02162771

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituxan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P10
Study: NCT00855010

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one daily
Study: NCT05956704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology with aspheric wide inversion zone design in the optical zone
Description: An orthokeratology lens with an altered optical zone design is designed for an aspherical wide inversion arc in the optical zone

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthokeratology with traditional spherical design in the optical zone
Description: Subjects wore the orthokeratology with traditional spherical design in the optical zone
Study: NCT02630095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin Calcium and Warfarin
Description: Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3, and during the of perioperative period of Endoscopic treatment changing to use Nadroparin Calcium 4100IU／d，subcutaneous.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound and CT
Description: all patient will take Doppler ultrasound examination every 3 months ；Abdominal CT will be done every 6 months。

Intervention type: DEVICE
Group type: OTHER
Intervention: Doppler ultrasound and CT
Description: all patient will take Doppler ultrasound examination every 3 months ；Abdominal CT will be done every 6 months。